Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01863953 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
A Phase 2 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT01863953 is a Phase 2 study of Glaucoma and Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 112 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01863953, a Phase 2 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Vehicle Ophthalmic Solution
- DRUG Fixed-Combination Bimatoprost/Brimonidine
- DRUG Bimatoprost Ophthalmic Solution 0.01%
- DRUG Brimonidine Tartrate Ophthalmic Solution 0.2%
Study Locations (1)
California
- - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01863953
The ClinicalTrials.gov registry entry for NCT01863953 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (88% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 4 interventions - of which Vehicle Ophthalmic Solution is the first listed.
NCT01863953 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01863953 about?
NCT01863953 is a clinical study titled "A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension". This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.
What is the current status of trial NCT01863953?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2013-06. Estimated completion is 2013-12.
What conditions does trial NCT01863953 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT01863953?
The interventions under investigation include: Vehicle Ophthalmic Solution (DRUG), Fixed-Combination Bimatoprost/Brimonidine (DRUG), Bimatoprost Ophthalmic Solution 0.01% (DRUG), Brimonidine Tartrate Ophthalmic Solution 0.2% (DRUG).
Who is sponsoring clinical trial NCT01863953?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01863953 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RECRUITING · Phase 2
-
Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration
ACTIVE NOT RECRUITING · Phase 2
-
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
ACTIVE NOT RECRUITING · Phase 2
-
Circadian Rhythms of Aqueous Humor Dynamics in Humans
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.